Shawn Olsson sold $261k of LENZ
Chief Commercial Officer at LENZ Therapeutics, Inc.. 10,000 shares at an average of $26.10, traded Nov 17, 2025, filed Nov 19, 2025.
Score components
- +15RoleOfficer
- +13Trade size$261k at market
- +20Share of holdings soldSold 68% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002015796-25-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | MOption exercise Common Stock10b5-1 | +10,000 | $2.08 | $21k | 14,733 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -4,212 | $25.74 | $108k | 10,521 | Nov 19, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -5,788 | $26.37 | $153k | 4,733 | Nov 19, 2025 |
| Nov 17, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 53,241 | Nov 19, 2025 |
Related signals
Other insiders at LENZ Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 66Notable | LENZ Therapeutics, Inc. | Daniel R. Chevallard Chief Financial Officer | $64k 7,500 shares | +139% | |
| 56Moderate | LENZ Therapeutics, Inc. | Jeffrey P. George director | $50k 5,592 shares | - | |
| 44Moderate | LENZ Therapeutics, Inc. | James W McCollum director | $239k 10,500 shares | - | |
| 47Moderate | LENZ Therapeutics, Inc. | Daniel R. Chevallard Chief Financial Officer | $50k 2,198 shares | +69% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $10M 224,974 shares | -19% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $5.7M 135,304 shares | -11% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $7.4M 188,094 shares | -13% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $10M 260,713 shares | -17% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $6.5M 191,376 shares | -11% | |
| 42Moderate | LENZsell LENZ Therapeutics, Inc. | Versant Venture Capital VI, L.P. owner | $6.1M 200,000 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.